By otakuyassine3@gmail.com 
AngioDynamics, Inc. (NASDAQ:ANGO – Get Free Report) was the recipient of a significant decrease in short interest during the month of December. As of December 15th, there was short interest totalling 1,000,000 shares, a decrease of 12.3% from the November 30th total of 1,140,000 shares. Based on an average daily trading volume, of 582,000 shares, the days-to-cover ratio is presently 1.7 days.
AngioDynamics Stock Down 1.1 %
NASDAQ:ANGO traded down $0.10 on Friday, hitting $8.91. The stock had a trading volume of 218,279 shares, compared to its average volume of 529,110. The company has a fifty day moving average price of $7.56 and a two-hundred day moving average price of $7.13. The stock has a market cap of $362.05 million, a price-to-earnings ratio of -1.46 and a beta of 0.68. AngioDynamics has a 1-year low of $5.26 and a 1-year high of $9.58.
AngioDynamics (NASDAQ:ANGO – Get Free Report) last posted its earnings results on Thursday, October 3rd. The medical instruments supplier reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.04. The company had revenue of $67.50 million for the quarter, compared to analysts’ expectations of $67.93 million. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. AngioDynamics’s revenue for the quarter was down 14.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.12) earnings per share. As a group, analysts anticipate that AngioDynamics will post -0.41 earnings per share for the current year.
Analysts Set New Price Targets
A number of analysts have recently commented on ANGO shares. Canaccord Genuity Group cut their price objective on AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, October 4th. HC Wainwright reiterated a “buy” rating and issued a $14.00 target price on shares of AngioDynamics in a research report on Tuesday, December 10th.
Check Out Our Latest Report on AngioDynamics
Insider Transactions at AngioDynamics
In other news, CEO James C. Clemmer acquired 20,000 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was acquired at an average price of $6.03 per share, for a total transaction of $120,600.00. Following the completion of the transaction, the chief executive officer now owns 681,582 shares in the company, valued at approximately $4,109,939.46. The trade was a 3.02 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have purchased 22,568 shares of company stock worth $135,847 over the last quarter. 5.40% of the stock is currently owned by insiders.
Institutional Trading of AngioDynamics
Hedge funds have recently made changes to their positions in the business. Segall Bryant & Hamill LLC increased its stake in AngioDynamics by 142.7% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 911,443 shares of the medical instruments supplier’s stock worth $7,091,000 after buying an additional 535,958 shares during the period. Millennium Management LLC increased its position in shares of AngioDynamics by 41.9% during the second quarter. Millennium Management LLC now owns 1,793,454 shares of the medical instruments supplier’s stock worth $10,850,000 after acquiring an additional 529,861 shares during the period. Systematic Financial Management LP raised its stake in shares of AngioDynamics by 14.3% in the third quarter. Systematic Financial Management LP now owns 2,410,346 shares of the medical instruments supplier’s stock valued at $18,752,000 after acquiring an additional 300,785 shares in the last quarter. First Eagle Investment Management LLC purchased a new position in AngioDynamics in the second quarter valued at $1,321,000. Finally, JPMorgan Chase & Co. grew its stake in AngioDynamics by 28.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 553,161 shares of the medical instruments supplier’s stock worth $4,304,000 after purchasing an additional 123,271 shares in the last quarter. Institutional investors and hedge funds own 89.43% of the company’s stock.
About AngioDynamics
AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.
Further Reading
Receive News & Ratings for AngioDynamics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AngioDynamics and related companies with MarketBeat.com’s FREE daily email newsletter.